TAVI global registry delivers 1st results | MassDevice.com On Call

October 3, 2012 by MassDevice staff

Edwards Lifesciences' transcatheter aortic valve implantation system proves effective in the 1st reports from a global registry of valve-in-valve TAVI patients, but safety issues raise eyebrows.

Updated October 3, 2012, at 9:45 p.m. to correct the lead story.

MassDevice On Call

MASSDEVICE ON CALL — The 1st reports from a global registry evaluating Edwards Lifesciences' (NYSE:EW) Sapien transcatheter aortic valve implantation inside a failing valve or mitral ring came with mixed results.*

The Sapien TAVI valve-in-valve procedure proved effective after 1 year, but in-hospital mortality proved a significant issue, affecting 10 of 91 patients, TheHeart.org reported.

"These deaths were mostly related to access-site bleeding and other major life-threatening bleeding events like tamponade," investigator Dr. Danny Dvir told the news site. "I hope that this is related to a learning-curve issue and that when many of the sites gain more experience doing these procedures we will see better early results.

Sign up to get our free newsletters delivered straight to your inbox

 Israeli device maker opens doors in Massachusetts
Isreal's Argo Medical Technologies plans to open a new headquarters in Marlborough, Mass., where the "exoskeleton" maker will hire up to 40 employees to work on the walking assistance technology for paraplegics.  
Read more